TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Observer-blind Safety and Reactogenicity Study to Assess GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women
Brief Summary: The purpose of this study is to assess the safety and reactogenicity of a single intramuscular dose of GSK Biologicals' investigational RSV vaccine, in healthy, non-pregnant women aged 18 to 45 years.


Options:
A: Arm Label: Treatment Group A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline Placebo (0.5mL injection) | Arm Label: Treatment Group B; Type: EXPERIMENTAL; Interventions: Drug: RSV F vaccine (0.5mL injection) | Intervention Type: DRUG; Name: Saline Placebo (0.5mL injection); Assigned to Arm(s): Treatment Group A | Intervention Type: DRUG; Name: RSV F vaccine (0.5mL injection); Assigned to Arm(s): Treatment Group B
B: Arm Label: RSV LID cp ΔM2-2 Vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV LID cp ΔM2-2 Vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RSV LID cp ΔM2-2 Vaccine; Assigned to Arm(s): RSV LID cp ΔM2-2 Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: RSV group; Type: EXPERIMENTAL; Interventions: Biological: RSV vaccine GSK3003891A | Arm Label: Boostrix group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Boostrix | Intervention Type: BIOLOGICAL; Name: RSV vaccine GSK3003891A; Assigned to Arm(s): RSV group | Intervention Type: BIOLOGICAL; Name: Boostrix; Assigned to Arm(s): Boostrix group
D: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Induced Moderate HYPOthermia on Mortality in Cardiogenic Shock Patients Rescued by Veno-arterial ExtraCorporeal Membrane Oxygenation (ECMO)
Brief Summary: A multicenter, prospective, controlled, randomized (moderate hypothermia 33°C≤ T°C ≤34°C) during 24 hours ± 1h versus normothermia (36°C≤ T°C ≤37°C), comparative open trial will be conducted on two parallel groups of patients with cardiogenic shock treated with VA-ECMO.

The HYPO-ECMO trial will test the hypothesis that moderate hypothermia (temperature between 33°C≤ T°C ≤34°C) associated with VA-ECMO support results in a reduction in 30-day mortality in comparison with the normothermia group (36°C≤ T°C ≤37°C).


Options:
A: Arm Label: ECMO arm; Type: EXPERIMENTAL; Interventions: Device: ECMO (Quadrox®, Jostra®, Maquet®) | Arm Label: conventional arm; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional care | Intervention Type: DEVICE; Name: ECMO (Quadrox®, Jostra®, Maquet®); Assigned to Arm(s): ECMO arm | Intervention Type: OTHER; Name: conventional care; Assigned to Arm(s): conventional arm
B: Arm Label: Hyperinvasive arm; Type: EXPERIMENTAL; Interventions: Device: Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS | Arm Label: Standard arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: DEVICE; Name: Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS; Assigned to Arm(s): Hyperinvasive arm | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard arm
C: Arm Label: Moderate hypothermia; Type: EXPERIMENTAL; Interventions: Other: moderate hypothermia | Arm Label: Normothermia; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: moderate hypothermia; Assigned to Arm(s): Moderate hypothermia
D: Arm Label: One Group; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CO-OPerative Training For Stroke Rehabilitation: A Phase II Trial Examining Meta-Cognitive Strategy Training in Acute Stroke Rehabilitation
Brief Summary: Cognitive impairments occur frequently after stroke, and are associated with significant long-term activities of daily living (ADL) disability and poor quality of life. This research study will undertake an innovative approach addressing cognitive impairments, by examining a new patient-centered functionally-relevant rehabilitation intervention that teaches individuals with cognitive impairments to manage their deficits to reduce ADL disability.


Options:
A: Arm Label: Self-Management group-intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management group-intervention | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care | Intervention Type: BEHAVIORAL; Name: Self-Management group-intervention; Assigned to Arm(s): Self-Management group-intervention | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care
B: Arm Label: animal assisted therapy; Type: EXPERIMENTAL; Interventions: Other: animal assisted therapy | Arm Label: standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: standard therapy | Intervention Type: OTHER; Name: animal assisted therapy; Assigned to Arm(s): animal assisted therapy | Intervention Type: OTHER; Name: standard therapy; Assigned to Arm(s): standard therapy
C: Arm Label: CO-OP; Type: EXPERIMENTAL; Interventions: Behavioral: CO-OP | Arm Label: Attention Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: CO-OP; Assigned to Arm(s): CO-OP | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention Control
D: Arm Label: APT-II group; Type: EXPERIMENTAL; Interventions: Behavioral: Attention Process Training-II | Arm Label: standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Attention Process Training-II; Assigned to Arm(s): APT-II group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Do Smartphones Increase Linkage to and Retention in Care in Newly Diagnosed HIV-positive Patients in Johannesburg, South Africa: A Multisite Randomised Controlled Trial
Brief Summary: This randomized controlled trial evaluates the provision of individual patient laboratory results to newly diagnosed HIV positive smartphone users through a secure application (app) as a method to get them linked to and retained in care, and engage with educational materials purposefully developed to explain their results. Message prompts will also be used to alert patients that their results are ready and provide information on how to link to care, and assistance to re-link to care if they fall out of the health system for any reason. Prompts will be sent to patients to remind health care workers if they are due for repeat laboratory monitoring. The primary endpoint is linkage to care (a HIV-related laboratory test) at 6 months. The control group received standard of care.


Options:
A: Arm Label: Standard of Care (SoC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SoC + iTab; Type: ACTIVE_COMPARATOR; Interventions: Device: SoC + iTab | Intervention Type: DEVICE; Name: SoC + iTab; Assigned to Arm(s): SoC + iTab
B: Arm Label: mhealth intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mhealth intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mhealth intervention; Assigned to Arm(s): mhealth intervention
C: Arm Label: Smartphone-enabled app for linkage to care; Type: EXPERIMENTAL; Interventions: Other: Smartphone application, Device: Smartphone | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Smartphone application; Assigned to Arm(s): Smartphone-enabled app for linkage to care | Intervention Type: DEVICE; Name: Smartphone; Assigned to Arm(s): Smartphone-enabled app for linkage to care
D: Arm Label: Positive adjustment coping intervention; Type: EXPERIMENTAL; Interventions: Other: Positive adjustment coping intervention | Arm Label: Brainteaser; Type: OTHER; Interventions: Other: Brainteaser | Intervention Type: OTHER; Name: Positive adjustment coping intervention; Assigned to Arm(s): Positive adjustment coping intervention | Intervention Type: OTHER; Name: Brainteaser; Assigned to Arm(s): Brainteaser

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Do Smartphones Increase Linkage to and Retention in Care in Newly Diagnosed HIV-positive Patients in Johannesburg, South Africa: A Multisite Randomised Controlled Trial
Brief Summary: This randomized controlled trial evaluates the provision of individual patient laboratory results to newly diagnosed HIV positive smartphone users through a secure application (app) as a method to get them linked to and retained in care, and engage with educational materials purposefully developed to explain their results. Message prompts will also be used to alert patients that their results are ready and provide information on how to link to care, and assistance to re-link to care if they fall out of the health system for any reason. Prompts will be sent to patients to remind health care workers if they are due for repeat laboratory monitoring. The primary endpoint is linkage to care (a HIV-related laboratory test) at 6 months. The control group received standard of care.


Options:
A: Arm Label: LATCH Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: LATCH Intervention | Intervention Type: BEHAVIORAL; Name: LATCH Intervention; Assigned to Arm(s): LATCH Intervention
B: Intervention Type: BEHAVIORAL; Name: Pulse; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone reminder | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Mobile phone reminder | Intervention Type: BEHAVIORAL; Name: Mobile phone reminder; Assigned to Arm(s): Control, Intervention
D: Arm Label: Smartphone-enabled app for linkage to care; Type: EXPERIMENTAL; Interventions: Other: Smartphone application, Device: Smartphone | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Smartphone application; Assigned to Arm(s): Smartphone-enabled app for linkage to care | Intervention Type: DEVICE; Name: Smartphone; Assigned to Arm(s): Smartphone-enabled app for linkage to care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Arm Label: Same-Day Treatment Group; Type: EXPERIMENTAL; Interventions: Other: Same-Day Treatment | Intervention Type: OTHER; Name: Same-Day Treatment; Assigned to Arm(s): Same-Day Treatment Group | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard Group
B: Arm Label: Centralised Xpert®Ultra testing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Xpert Ultra Point of Care testing; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Xpert Ultra Point of Care testing | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert Ultra Point of Care testing; Assigned to Arm(s): Xpert Ultra Point of Care testing
C: Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): N/A
D: Arm Label: Pulmonary Tuberculosis Suspects; Type: N/A; Interventions: Diagnostic Test: CRISPR-based Test | Intervention Type: DIAGNOSTIC_TEST; Name: CRISPR-based Test; Assigned to Arm(s): Pulmonary Tuberculosis Suspects

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Arm Label: Same-Day Treatment Group; Type: EXPERIMENTAL; Interventions: Other: Same-Day Treatment | Intervention Type: OTHER; Name: Same-Day Treatment; Assigned to Arm(s): Same-Day Treatment Group | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard Group
B: Arm Label: PLHIV Centralised Xpert Ultra; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PLHIV Point of Care Xpert Ultra; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: PLHIV Point of Care Xpert Ultra | Arm Label: PLHIV Centralised Xpert VL; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PLHIV Point of Care Xpert VL; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: PLHIV Point of Care Xpert VL | Intervention Type: DIAGNOSTIC_TEST; Name: PLHIV Point of Care Xpert Ultra; Assigned to Arm(s): PLHIV Point of Care Xpert Ultra | Intervention Type: DIAGNOSTIC_TEST; Name: PLHIV Point of Care Xpert VL; Assigned to Arm(s): PLHIV Point of Care Xpert VL
C: Arm Label: Intervention; Type: OTHER; Interventions: Diagnostic Test: LF-LAM | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIAGNOSTIC_TEST; Name: LF-LAM; Assigned to Arm(s): Intervention
D: Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Arm Label: Case Detection Group; Type: N/A; Interventions: Diagnostic Test: Truenat MTB | Arm Label: Drug Resistant TB Group; Type: N/A; Interventions: Diagnostic Test: Truenat MTB | Intervention Type: DIAGNOSTIC_TEST; Name: Truenat MTB; Assigned to Arm(s): Case Detection Group, Drug Resistant TB Group
B: Arm Label: Bedaquiline + PA-824 + Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: PA-824, Drug: Linezolid | Intervention Type: DRUG; Name: Bedaquiline; Assigned to Arm(s): Bedaquiline + PA-824 + Linezolid | Intervention Type: DRUG; Name: PA-824; Assigned to Arm(s): Bedaquiline + PA-824 + Linezolid | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Bedaquiline + PA-824 + Linezolid
C: Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): N/A
D: Arm Label: Centralised Xpert®Ultra testing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Xpert Ultra Point of Care testing; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Xpert Ultra Point of Care testing | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert Ultra Point of Care testing; Assigned to Arm(s): Xpert Ultra Point of Care testing

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Arm Label: GeneXpert; Type: ACTIVE_COMPARATOR; Interventions: Other: GeneXpert, Other: LED Microscopy | Arm Label: LED Microscopy; Type: ACTIVE_COMPARATOR; Interventions: Other: LED Microscopy | Intervention Type: OTHER; Name: GeneXpert; Assigned to Arm(s): GeneXpert | Intervention Type: OTHER; Name: LED Microscopy; Assigned to Arm(s): GeneXpert, LED Microscopy
B: Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): N/A
C: Arm Label: Case Detection Group; Type: N/A; Interventions: Diagnostic Test: Truenat MTB | Arm Label: Drug Resistant TB Group; Type: N/A; Interventions: Diagnostic Test: Truenat MTB | Intervention Type: DIAGNOSTIC_TEST; Name: Truenat MTB; Assigned to Arm(s): Case Detection Group, Drug Resistant TB Group
D: Arm Label: Community level screening; Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Screening at community level | Arm Label: Community level screening: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Screening at community level | Intervention Type: DIAGNOSTIC_TEST; Name: Screening at community level; Assigned to Arm(s): Community level screening: Arm 2, Community level screening; Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): N/A
B: Intervention Type: OTHER; Name: Development of a diagnosis algorithm; Assigned to Arm(s): N/A
C: Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Arm Label: Same-Day Treatment Group; Type: EXPERIMENTAL; Interventions: Other: Same-Day Treatment | Intervention Type: OTHER; Name: Same-Day Treatment; Assigned to Arm(s): Same-Day Treatment Group | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard Group
D: Arm Label: Centralised Xpert®Ultra testing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Xpert Ultra Point of Care testing; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Xpert Ultra Point of Care testing | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert Ultra Point of Care testing; Assigned to Arm(s): Xpert Ultra Point of Care testing

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Arm Label: Same-Day Treatment Group; Type: EXPERIMENTAL; Interventions: Other: Same-Day Treatment | Intervention Type: OTHER; Name: Same-Day Treatment; Assigned to Arm(s): Same-Day Treatment Group | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard Group
B: Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: OTHER; Interventions: Diagnostic Test: LF-LAM | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIAGNOSTIC_TEST; Name: LF-LAM; Assigned to Arm(s): Intervention
D: Arm Label: Case Detection Group; Type: N/A; Interventions: Diagnostic Test: Truenat MTB | Arm Label: Drug Resistant TB Group; Type: N/A; Interventions: Diagnostic Test: Truenat MTB | Intervention Type: DIAGNOSTIC_TEST; Name: Truenat MTB; Assigned to Arm(s): Case Detection Group, Drug Resistant TB Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tuberculosis Research of INA-RESPOND On Drug Resistance
Brief Summary: This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.


Options:
A: Arm Label: PLHIV Centralised Xpert Ultra; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PLHIV Point of Care Xpert Ultra; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: PLHIV Point of Care Xpert Ultra | Arm Label: PLHIV Centralised Xpert VL; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PLHIV Point of Care Xpert VL; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: PLHIV Point of Care Xpert VL | Intervention Type: DIAGNOSTIC_TEST; Name: PLHIV Point of Care Xpert Ultra; Assigned to Arm(s): PLHIV Point of Care Xpert Ultra | Intervention Type: DIAGNOSTIC_TEST; Name: PLHIV Point of Care Xpert VL; Assigned to Arm(s): PLHIV Point of Care Xpert VL
B: Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): N/A
C: Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Arm Label: Same-Day Treatment Group; Type: EXPERIMENTAL; Interventions: Other: Same-Day Treatment | Intervention Type: OTHER; Name: Same-Day Treatment; Assigned to Arm(s): Same-Day Treatment Group | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard Group
D: Arm Label: Pulmonary Tuberculosis Suspects; Type: N/A; Interventions: Diagnostic Test: CRISPR-based Test | Intervention Type: DIAGNOSTIC_TEST; Name: CRISPR-based Test; Assigned to Arm(s): Pulmonary Tuberculosis Suspects

Answer: B